Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
Closed for Enrollment
-
A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of TAK-062 For The Treatment Of Active Celiac Disease In Subjects Attempting A Gluten-Free Diet
Scottsdale/Phoenix, AZ
Rochester, MN
The purpose of this study is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
-
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study To Evaluate The Efficacy, Safety, And Pharmacodynamics Of RM-131 Administered To Patients With Chronic Constipation
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate safety and tolerability as well as the effects of RM-131 on colonic transit, bowel consistency, bowel habits, abdominal pain, and other abdominal symptoms in patients with chronic constipation.
-
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of The Efficacy And Safety Of ALV003 Treatment In Symptomatic Celiac Disease Patients Maintained On A Gluten-Free Diet
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.
-
Obesity and Irritable Bowel Syndrome (IBS): Assessment of Co-morbidity and Interactions with Gut Microbiota, Vitamin D and Serotonin Levels
Scottsdale/Phoenix, AZ
This study will evaluate obesity as a comorbidity in a population of patients with irritable bowel syndrome (IBS), and assess this cohort for vitamin D-deficiency. It will also determine whether alterations in the fecal microbiome and metaproteome, associated with vitamin D deficiency or other factors, underpin obesity-IBS comorbidity.
.